Position in GNLX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$92,581
+$18,148 QoQ
Shares Held
30,758
0.0% QoQ
Ownership
0.068%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#35
of 72 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GNLX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RAYMOND JAMES FINANCIAL INC holds $1,702,332,948 across 201 Biotechnology names. GNLX ranks #167 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
556,876 | $276,617,014 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
392,799 | $118,244,281 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
172,896 | $107,807,571 | |
| 4 | RPRX |
Royalty Pharma plc
|
1,599,881 | $89,705,325 | |
| 5 | INSM |
INSMED Inc
|
660,601 | $70,433,276 | |
| 6 | KRYS |
Krystal Biotech, Inc.
|
158,675 | $58,974,733 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
228,645 | $55,096,584 | |
| 8 | EXEL |
Exelixis, Inc.
|
941,571 | $51,230,875 |
All Filings in GNLX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $92,581 | 30,758 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $74,433 | 30,758 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $134,104 | 30,758 | Shares | Defined | 2026-02-18 | |
| 2025-09-30 | $129,183 | 30,758 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $83,037 | 28,933 | Shares | Defined | 2025-08-14 | |
| 2025-03-31 | $63,720 | 23,600 | Shares | Defined | 2025-05-13 | |
| 2024-12-31 | $40,710 | 17,250 | Shares | Defined | 2025-04-23 | |
| No filing history on record for this holder in this stock. | ||||||